1. Home
  2. BVN vs PRAX Comparison

BVN vs PRAX Comparison

Compare BVN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buenaventura Mining Company Inc.

BVN

Buenaventura Mining Company Inc.

N/A

Current Price

$19.51

Market Cap

6.9B

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$303.07

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BVN
PRAX
Founded
1953
2015
Country
Peru
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
7.1B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
BVN
PRAX
Price
$19.51
$303.07
Analyst Decision
Hold
Strong Buy
Analyst Count
6
20
Target Price
$36.83
★ $677.32
AVG Volume (30 Days)
★ 1.0M
418.5K
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 5.35%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.16
N/A
Revenue Next Year
N/A
$55,537.76
P/E Ratio
$21.78
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$21.21
$167.32
52 Week High
$44.67
$392.70

Technical Indicators

Market Signals
Indicator
BVN
PRAX
Relative Strength Index (RSI) 19.10 51.40
Support Level N/A $281.96
Resistance Level $36.50 $349.92
Average True Range (ATR) 1.21 20.40
MACD -0.61 0.11
Stochastic Oscillator 4.60 45.17

Price Performance

Historical Comparison
BVN
PRAX

About BVN Buenaventura Mining Company Inc.

Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: